Mode
Text Size
Log in / Sign up
Phase 3 N=117 Treatment

Convalescent Plasma Collection and Treatment in Pediatrics and Adults

COVID19 · Coronavirus Infection · Coronavirus · Virus Diseases · RNA Virus Infections

Enrolled (actual)
117
Serious AEs
13.7%
Results posted
May 2026
Primary outcome: Primary: Time of Meeting Infusion Criteria to Infusion — 1 days

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Convalescent Plasma (Biological)
Age
Pediatric, Adult, Older Adult · 0+ yrs
Sex
All
Sponsor
West Virginia University
Primary completion
Feb 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Time of Meeting Infusion Criteria to Infusion
1
PRIMARY
Plasma Recipient Survival
90
PRIMARY
Identify Plasma Donor
PRIMARY
Outreach to Plasma Donor
PRIMARY
Plasma Donor Time Until Donated
SECONDARY
Plasma Recipient Mortality
22
SECONDARY
Plasma Recipient LOS
23.6
SECONDARY
Plasma Recipient AE (Day 1)
4
SECONDARY
Plasma Recipient AE (Day 2)
SECONDARY
Plasma Recipient AE (Day 3)
SECONDARY
Plasma Recipient AE (Day 4)
1
SECONDARY
Plasma Recipient AE (Day 5)
SECONDARY
Plasma Recipient AE (Day 6)
1
SECONDARY
Plasma Recipient AE (Day 7)
SECONDARY
Plasma Recipient AE (Day 30)

Summary

This is a prospective study, using plasma to help fight off infections of those suffering from COVID-19 in accordance with collection guidelines for plasma and FDA IND requirements. This study included up to 240 participants potentially receiving convalescent plasma. NOTE: West Virginia does not have any entity with the required FDA registration/licensure or necessary equipment to collect convalescent plasma for transfusion. Therefore, the plasma donation portion of this study was not completed.

Eligibility Criteria

Inclusion Criteria: (NOTE: It is important to note that West Virginia, as a state, does not have any entity with the required FDA registration or licensure, nor the necessary on-site equipment, to collect convalescent plasma for the purpose of plasma transfusion. Therefore, the plasma donation portion of this study was not completed).

  • Plasma donation:
  • Prior diagnosis of COVID-19 documented by a laboratory test
  • Abbott RealTime SARS-CoV-2 real-time reverse transcription polymerase chain reaction (rRT-PCR) test on the Abbott m2000 System (Inpatient WVU testing)
  • Other testing methods and vendors using FDA approved detection methods of SARS-CoV-2 under the Emergency Use Authorization (EUA)
  • Complete resolution of symptoms at least 28 days prior to donation
  • Complete resolution of symptoms for at least 14 days with negative repeat COVID-19 testing approved by the FDA EUA
  • Female donors age 18+ that have never been pregnant or negative for HLA antibodies
  • Male donors age 18+
  • Negative results for COVID-19 either from one or more nasopharyngeal swab specimens or by a molecular diagnostic test from blood. A partial list of available tests can be accessed at https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations.
  • Defined SARS-CoV-2 neutralizing antibody titers, if testing can be conducted (e.g., of at least 1:1602, 1:360 up to 1:640 is preferred. In shortage case 1:80 is acceptable)
  • At least or greater than 50kg of weight
  • Plasma Recipients:
  • Individuals of any age above 30 days of life, sex, or pregnancy status suffering from confirmed COVID19 and in rapid progression, severe or critical condition meeting the FDA IND guidelines.
  • Must have laboratory confirmed COVID19
  • Must have severe or immediately life-threatening COVID19
  • Must provide informed consent/assent

Exclusion Criteria

  • Plasma donation:
  • Individuals that do not meet the requirement from the American Red Cross for plasma donation or equivalent
  • Individuals plasma that has not passed safety screening after procurement by the American Red Cross for plasma donation or equivalent
  • Plasma Recipients
  • Individuals with COVID19 who are not in clinical concern for rapid progression, severe or critical condition
  • Individuals who are in critical condition that are not confirmed to have COVID19
  • Individuals with known Selective IgA Deficiency, that has not been found to be absent of anti-IgA antibodies
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04376034). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search